Medications
Insights into brigatinib's rare side effects may help more lung cancer patients benefit from the drug
Brigatinib is a next-generation ALK inhibitor that earned FDA approval in 2017 as a second-line therapy after treatment with crizotinib for ALK-positive non-small cell lung cancer. Recently, clinical trial results published ...
May 21, 2019
0
6
